Key facts
- This page summarizes Ph.D. Noubar B. Afeyan's Form 4 filing for Moderna, Inc. (MRNA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 May 2026, 19:00.
Ph.D. Noubar B. Afeyan - 21 May 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Director
- Issuer ticker
- MRNA
- Reported as of
- 21 May 2026
- Net transaction value
- -$433,879
- SEC form
- 4
- Accepted by SEC
- 22 May 2026, 19:00:04 UTC
- Prior SEC filing
- 08 May 2026
- Source filing
- View source filing
- Reporting owner signature
- Noubar B. Afeyan, Ph.D. By: /s/ Noubar B. Afeyan, Ph.D.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ph.D. Noubar B. Afeyan filed Form 4 for Moderna, Inc. (MRNA) on 22 May 2026.
Change
- Previous filing in this sequence was filed on 08 May 2026.
- Current net transaction value: -$433,879.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001222012
Primary reporting owner
AFEYAN NOUBAR
- Relationship
- Director
- Address
- C/O FLAGSHIP PIONEERING, 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE
- Signature
- Noubar B. Afeyan, Ph.D. By: /s/ Noubar B. Afeyan, Ph.D.
- Signature date
- 22 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +9,263
- Change %
- +236%
- Price
- $19.15*
- Shares after
- 13,187
- Date
- 21 May 2026
- Ownership
- By Flagship Pioneering, LLC
- Footnotes
- F1, F2
MRNA
transaction
Common Stock
Sale
- Transaction value
- $433,879
- Shares
- -9,263
- Change %
- -70%
- Price
- $46.84
- Shares after
- 3,924
- Date
- 21 May 2026
- Ownership
- By Flagship Pioneering, LLC
- Footnotes
- F2
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,880,328
- Date
- 21 May 2026
- Ownership
- By Flagship Ventures Fund IV, L.P.
- Footnotes
- F3
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 747,897
- Date
- 21 May 2026
- Ownership
- By Flagship Ventures Fund IV-Rx, L.P.
- Footnotes
- F4
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,224,015
- Date
- 21 May 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -9,263
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 May 2026
- Ownership
- By Flagship Pioneering, LLC
- Underlying class
- Common Stock
- Underlying amount
- 9,263
- Exercise price
- $19.15
- Footnotes
- F1, F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
On May 21, 2026, Flagship Pioneering, LLC ("Flagship Pioneering") exercised options to purchase 9,263 shares of the Issuer's Common Stock at $19.15 per share, which options were set to expire on August 10, 2026.
Footnote F2
The securities are held directly by Flagship Pioneering. Flagship Pioneering is contractually obligated to transfer and/or remit the proceeds of any sale of shares to Flagship Fund IV, L.P. ("Flagship Fund IV"). The reporting person is the ultimate control person of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Footnote F3
The securities are held directly by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Footnote F4
The securities are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Footnote F5
The options were fully vested and exercisable.